PGNY vs. CRL: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Sep 18, 2026

Progyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027

Progyny (PGNY) remains the US market leader in fertility benefits management, demonstrating robust growth, improving margins, and a compelling valuation despite recent volatility. PGNY's Q2 2026 results highlight 11% revenue growth ex-Amazon, margin expansion, and nearly 100% EPS growth guidance for 2026, supporting a continued buy rating. Secular tailwinds—rising infertility rates, delayed family formation, and underpenetrated employer markets—position PGNY for sustained double-digit growth and market share gains.

Seeking Alpha • Sep 17, 2026

Wall Street Analysts Predict a 25.23% Upside in Progyny (PGNY): Here's What You Should Know

The mean of analysts' price targets for Progyny (PGNY) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Sep 9, 2026

Progyny, Inc. to Present at the Wells Fargo Healthcare Conference

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Tuesday, September 8, 2026, at 11:00 a.m. ET.

GlobeNewsWire • Sep 3, 2026

Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns

MNDY, MTCH, PGNY and WK make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.

Zacks Investment Research • Aug 24, 2026

Progyny Sees Utilization Rebound as Early Renewals De-Risk Outlook

Progyny NASDAQ: PGNY CEO Pete Anevski said the company expects member engagement and utilization to rebound following a more pronounced summer seasonal slowdown, while early renewal and new-client commitments have increased management's confidence in its outlook for the remainder of the year.

MarketBeat • Aug 16, 2026

Boost Your Portfolio Returns With These 4 Top-Ranked Liquid Stocks

IVZ, HUBS, HNGE and PGNY make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.

Zacks Investment Research • Aug 10, 2026

Why Progyny Stock Plunged, Then Gradually Recovered Today

Progyny's sales and adjusted earnings per share grew by 5% and 15% in the second quarter. However, management's conservative guidance for 7% to 11% revenue growth in Q3 worried the market.

The Motley Fool • Aug 7, 2026

Progyny Q2 Earnings Call Highlights

Progyny NASDAQ: PGNY reported record quarterly revenue, gross profit and adjusted EBITDA for the second quarter of 2026, while management said early sales commitments and client-retention activity have positioned the company favorably for the 2027 selling season.

MarketBeat • Aug 7, 2026

Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET.

GlobeNewsWire • Aug 7, 2026